1.   中华人民共和国科学技术部，精准医学研究专项项目，2017YFC0908103，《肝癌/肝病临床和社区人群大型队列研究》子课题三《肝癌高危人群社区队列研究》，2017-07-01至2021-6-30，结题，主持（负责人）

2.  DNA聚合酶家族作为肝癌免疫治疗疗效标志谱的临床评价，中国医学科学院，临床研究专项，2021-9至2023-9，在研，主持（负责人）

3.  TERT相关的DNA 聚合酶基因家族通过募集 CD8 阳性 T 细胞作为免疫治疗敏感性标志物的研究，CSCO项目基金，2021-6至2023-6，在研，主持（负责人）

4.  结直肠癌肝转移免疫相关分子分型的构建及验证，CSCO项目基金，2021-1至2023-1，在研，主持（负责人）

5.  甲磺酸仑伐替尼片术后辅助治疗胆道肿瘤患者的非随机、单中心前瞻性临床队列研究，2020-1至2022-1，在研，主持（负责人）

6.  中国医学科学院肿瘤医院，院内临床课题，LC2016A07，术前放疗降低肝细胞癌术后复发的探索性研究，2016-10-01至2019-09-30，已结题，主持（负责人）

一、期刊论文

1.       Zhiwen Luo; Xiao Chen; Yefan Zhang; Zhen Huang; Hong Zhao; Jianjun Zhao; Zhiyu Li; Jianguo Zhou; Jianmei Liu; Jianqiang Cai; Xinyu Bi^*; Development of a Metastasis-Related Immune Prognostic Model of Metastatic Colorectal Cancer and Its Usefulness to Immunotherapy., Frontiers in Cell and Developmental Biology, 2021, 8: 577125. 

1.       Zhao Y, Li Y, Sheng J, Wu F, Li K, HuangR, Wang X, Jiao T, Guan X, Lu Y, Chen X, Luo Z, Zhou Y, Hu H, Liu W, Du B, MiaoS, Cai J, Wang L, Zhao H, Ying J, Bi X*, Song W. P53-R273Hmutation enhances colorectal cancer stemness through regulating specificlncRNAs. J Exp Clin Cancer Res. 2019 Aug 28;38(1):379. doi:10.1186/s13046-019-1375-9. PMID: 31455383; PMCID: PMC6712617.

2.       Dazhuang Ge,Zhiwen Luo,Rui Mao,HongZhao,Xueyan Lv,Jianjun Zhao,Jianguo Zhou,Zhen Huang,Yefan Zhang,Zhiyu Li,XinyuBi,Jianqiang Cai. Development and Validation of a Nomogram-Based PrognosticEvaluation Model for Sarcomatoid Hepatocellular Carcinoma. Adv Ther.2020;37(7):3185-3205.

3.       Zhiwen Luo; Hong Zhao; Zhiyu Li; Rui Mao;Jianjun Zhao; Dazhuang Ge; Fengying Zhang; Yanchi Zhou; Xiao Chen; JianqiangCai; Xinyu Bi*; 604P Development and validation of ametastasis-associated immune prognostic model for concurrent metastaticcolorectal cancer[J].Annals of Oncology, Volume 30, Issue Supplement_5, October2019, mdz246.081.

4.       Chen X, Yan S, Zhao H, Zhang Y, Huang Z,Zhao J, Zhou J, Li Z, Bi X*, Cai J*. The safety and feasibility of a singleincision in simultaneous resection for patients with colorectal cancer livermetastases. Ann Transl Med. 2019 Oct;7(20):547. doi: 10.21037/atm.2019.09.93.PMID: 31807529; PMCID: PMC6861763.

5.       Zhiwen Luo, Xinyu Bi*. Recurrenceafter surgery for concurrent metastatic colorectal cancer: The perspective ofbioinformatics and machine learning[J]. J Clin Oncol 38: 2020 (suppl; abstr4043)

6.       Zhiwen Luo, Xinyu Bi*. Effect of alncRNA-associated ceRNA regulatory network in MVI-positive hepatocellularcarcinoma on their sensitivity to sorafenib[J]. J Clin Oncol 38: 2020 (suppl;abstr e16615)

7.       Li Y, Bi X#, Zhao J, Huang Z, ZhouJ, Li Z, Zhang Y, Li M, Chen X, Hu X, Chi Y, Zhao D, Zhao H, Cai J. CEA Level,Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for PatientsWith Locoregional Gastrin-Independent GNET. Medicine (Baltimore). 2016May;95(18):e3567. doi: 10.1097/MD.0000000000003567. PMID: 27149478; PMCID:PMC4863795.

8.       Li Z, Wu X, Bi X*, ZhangY, Huang Z, Lu H, Zhao H, Zhao J, Zhou J, Li M, Ying J, Cai J.Clinicopathological features and surgical outcomes of four rare subtypes ofprimary liver carcinoma. Chin J Cancer Res. 2018 Jun;30(3):364-372. doi:10.21147/j.issn.1000-9604.2018.03.08. PMID: 30046230; PMCID: PMC6037584.

9.       Li MX#, Bi XY#, Li ZY, Huang Z, HanY, Zhao JJ, Zhao H, Cai JQ. Impaction of surgical margin status on the survivaloutcome after surgical resection of intrahepatic cholangiocarcinoma: asystematic review and meta-analysis. J Surg Res. 2016 Jun 1;203(1):163-73. doi:10.1016/j.jss.2016.02.012. Epub 2016 Feb 18. PMID: 27338547.

10.      Li MX#, BiXY#, Huang Z, Zhao JJ, Han Y, Li ZY, Zhang YF, Li Y, Chen X, Hu XH, Zhao H,Cai JQ. Prognostic Role of Phospho-STAT3 in Patients with Cancers of theDigestive System: A Systematic Review and Meta-Analysis. PLoS One. 2015 May29;10(5):e0127356. doi: 10.1371/journal.pone.0127356. PMID: 26024373; PMCID:PMC4449159.

11.      Hu X,Huang Z, Zhang Y, Chen X, Zhao H, Bi X*. Primary hepatic neuroendocrinetumor: report of one case. Transl Gastroenterol Hepatol. 2016 Oct 29;1:82. doi:10.21037/tgh.2016.10.02. PMID: 28138647; PMCID: PMC5244638.

12.      Li C(#),Bi X(#), Huang Y(#), Zhao J, Li Z, Zhou J, Zhang M, Huang Z, Zhao H, CaiJ. Variants identified by hepatocellular carcinoma and chronic hepatitis Bvirus infection susceptibility GWAS associated with survival in HBV-relatedhepatocellular carcinoma, PLoS One, 2014,9(7):e101586.

13.      Li C(#),Zhao H, Zhao J, Li Z, Huang Z, Zhang Y, Bi X(*), Cai J(*). Prognosis of patientswith hepatocellular carcinoma and hypersplenism after surgery: a single-centerexperience from the People's Republic of China, Onco Targets Ther,2014,7:957-64.

14.      ZhouJ(#), Yan T(#), Bi X(#), Zhao H, Huang Z, Zhang Y, Li Y, Feng L, Wang J,Cai J(*), Evaluation of seven different staging systems for alpha-fetoproteinexpression in hepatocellular carcinoma after hepatectomy, Tumour Biol,2013,34(2):1061-1070

15.      Bi X(#), Han X,Zhang F, He M, Zhang Y, Zhi XY(*), Zhao H(*), Triparanol suppresses human tumorgrowth in vitro and in vivo, Biochem Biophys Res Commun, 2012,425(3):613-8.

16.      罗治文，陈晓，张业繁，黄振，赵宏，赵建军，李智宇，周健国，蔡建强，毕新宇*.机器学习算法和COX列线图在肝细胞癌术后生存预测中的应用价值[J].中华消化外科杂志,2020,19(2):166-178.

17.      胡旭辉, 张业繁, 冯勤付, 毕新宇*. 倾向性评分匹配法评估手术联合术中放疗在肝癌治疗中的安全性及有效性. 医学研究杂志. 2017. 46(5):43-47.

18.      毕新宇, 黄振, 王健等. 90例老年胃间质瘤患者手术治疗及预后分析. 医学研究杂志. 2013. 42(6):45-48.

二、会议论文

(1) Zhiwen Luo, Xinyu Bi*;604P Development and validation of a metastasis-associated immune prognosticmodel for concurrent metastatic colorectal cancer. Annals of Oncology 2019; 30.European Society for Medical Oncology 2019 (ESMO 2019), 巴塞罗那，西班牙，2019-9-26至2019-10-2。

(2) 罗治文，毕新宇*；结直肠癌肝转移的术后复发：机器学习和生物信息学的观点，第十七届全国肝癌学术大会，中国，上海，2019-12-5至2019-12-9。

(3) 罗治文，毕新宇*；生存分析构建和验证肝肉瘤样癌的预后模型，中国肿瘤学大会，中国，重庆，2019-7-10至2019-7-13。

(4) Zhiwen Luo，Xinyu Bi*；Immune prognostic modelfor predicting the recurrence and response to chemo/immunotherapy in metastaticcolorectal cancer，American Society ofClinical Oncology 2020（ASCO2020），美国，芝加哥，2020-5-29至2020-6-2。

(5) Zhiwen Luo, Xinyu Bi*;A lncrna-associated cerna regulatory network in mvi positive hepatocellularcarcinoma influences their sensitivity to sorafenib, International LiverCongress 2020, EASL 2020, 伦敦，英国，2020-8-25至2020-8-29。

(6) Zhiwen Luo, Xinyu Bi*; Comprehensive analysis of a microvascular invasion related ceRNA network reveals a potential prognostic lncRNAs signature involved in hepatocellular carcinoma progression and sorafenib resistance. European Society for Medical Oncology 2020 (ESMO 2020)

(7) Zhiwen Luo, Xinyu Bi*; TERT-associated DNA polymerases genes link CD8+ T cells to improve immunotherapy response rate. European Society for Medical Oncology 2020 (ESMO 2020)

(1) 毕新宇(1/1); 第一届全国肝脏、胰腺、胃肠手术展演暨“中华外科金手指奖“评比, 中华医学会外科学分会, 其他, 国家二等奖, 2016(毕新宇). 

(2) 毕新宇(9/10); 直肠癌综合治疗关键技术的建立、优化及推广, 北京市科委, 科技进步, 省部二等奖, 2014(周志祥; 蔡建强; 金晶; 冉宇靓; 欧阳汉; 梁建伟; 王勇; 侯惠荣; 毕新宇; 赵宏). 

(3) 毕新宇(5/8); 结直肠癌综合治疗关键技术的优化与推广应用, 中华医学会, 科技进步, 其他, 2014(蔡建强; 周志祥; 金晶; 应建明; 毕新宇; 赵宏; 梁建伟; 侯惠荣). 

(4) 毕新宇(7/15); 结直肠癌综合治疗关键技术的优化与推广应用, 中国医疗保健国际交流促进会, 科技进步, 省部一等奖, 2013(蔡建强; 周志祥; 金晶; 应建明; 冉宇靓; 王勇; 毕新宇; 赵宏; 梁建伟; 姜军; 杨林; 依荷芭丽迟; 侯惠荣; 孙力超; 杨治华).